SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells
Hideki Terai(Kitasato Institute Hospital), Koichi Fukunaga(Keio University), Sohei Nakayama(Beth Israel Deaconess Medical Center), Tadashi Manabe(Keio University), Kenzo Soejima(Keio University), Satoshi Kuronuma(Kitasato Institute Hospital), Takeshi Masuda(Kumamoto University), Keigo Kobayashi(Osaka Gakuin University), Sumio Ohtsuki(Kumamoto University), Keita Masuzawa(Kitasato Institute Hospital), Shinnosuke Ikemura(Keio University), Katsura Emoto(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Junko Hamamoto(Keio University), Ichiro Kawada(Keio University), Yukio Suzuki(Gifu University Hospital), Osamu Takeuchi(Kitasato Institute Hospital), Yusuke Suzuki(Keio University)
Cited by 21
Related Papers
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
|Nature Medicine|2018|317
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
Global metabolic network reorganization by adaptive mutations allows fast growth of Escherichia coli on glycerol
|Nature Communications|2014|115